IPSC NASDAQ
Philadelphia, PA 19104
US
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Pfeiffenberger Brent | F-InKind | 31,172 | $2.34 | 2026-05-15 |
| Carr Douglas | S-Sale | 264 | $2.34 | 2026-05-04 |
| Cowan Chad | F-InKind | 1,365 | $2.19 | 2026-04-01 |
| Carr Douglas | S-Sale | 7,043 | $2.55 | 2026-03-12 |
| Russotti Gregory | S-Sale | 10,076 | $2.55 | 2026-03-12 |